2023-12-26 06:07:00
Treatments
Revolution in sight on drugs for diabetes and obesity?
GLP-1 analogue treatments have disrupted the diabetes and obesity market. Last March, we took stock of these drugs while tirzepatide was approved in Europe for weight loss a few days ago.
Strategy
Oncology: How Pfizer is preparing for the post-Covid era by taking over Seagen
Pfizer signs the acquisition of the year. An operation made official a few weeks ago and which allows the American giant to strengthen its position in cancer treatments.
And also: Beyond EuroAPI’s downward forecasts, should we be worried regarding CDMOs?
Flash radiotherapy aims to reduce cancer
Already used for decades, radiotherapy continues to evolve to fight cancer.
Reportage
Visit to the Novo Nordisk site in Chartres, stronghold of the manufacturing of products once morest diabetes
Report on the flagship Novo Nordisk site in France, a few months before the €2.1 billion investment announcement
Services
Sartorius Stedim Biotech takes over the Alsatian company Polyplus
In March 2023, Sartorius Stedim Biotech acquired Polyplus, a specialist in transfection reagents, for 2.4 billion euros. A major transaction, a sign of the importance of reagents intended for bioproduction.
Clinical results
Incyte’s Opzelura approved once morest vitiligo in Europe
The cream treatment became the first drug approved in Europe to repigment non-segmental vitiligo.
And also : Sanofi’s Dupixent effective once morest COPD
French biotechs in the spotlight
Amolyt Pharma raises 130 million euros
From the start of 2023, the Lyon biotech company signed a major fundraising effort to move forward with these treatments once morest rare endocrine diseases.
Vect-Horus signs a potentially €327 million deal with Novo Nordisk
At the end of October, the Marseille biotech signed an agreement to develop vectors for the Danish giant.
Selected for you
1703641044
#read #articles #Industrie #Pharma
